Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Atripla

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Atripla was produced by Gilead Sciences.

ViiV bags US approval for HIV blockbuster-in-waiting

ViiV bags US approval for HIV blockbuster-in-waiting At the moment the HIV fixed-dose combination market is led by Gilead's Atripla (tenofovir, emtricitabine and efavirenz) with sales of $3.65bn last year. ... In SINGLE 80 per cent of subjects on the dolutegravir-based regimen were virologically suppressed

A new option for people with HIV

A new option for people with HIV versus that with efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla; Bristol-Myers Squibb, Gilead Sciences) in 833 ART-naïve patients with HIV-1 infection. ... dolutegravir vs 83 per cent of patients with Atripla), or more than 100, 000

ViiV's Tivicay for HIV on course for EU approval

ViiV's Tivicay for HIV on course for EU approval efficacy in patients with resistance to the class and out-performed Gilead's big-selling Atripla (efavirenz/emtricitabine/tenofovir DF) brand in the phase III SINGLE trial. . ... In studies Stribild was only able to demonstrate non-inferiority to Atripla

ViiV gets US nod for HIV drug dolutegravir

ViiV gets US nod for HIV drug dolutegravir Atripla (efavirenz/emtricitabine/tenofovir) when given alongside Ziagen (abacavir) and Zeffix (lamivudine).

EU recommendations for Gilead, Ariad and Baxter drugs

EU recommendations for Gilead, Ariad and Baxter drugs Atripla, as well as to a regimen containing ritonavir-boosted atazanavir plus Truvada.

[ Previous 5 results ] 1 2 3 4 5 6 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics